Creso Pharma launches product into New Zealand
By Administrator | 5 July 2018
Listed cannabis company Creso Pharma is set to launch its chronic pain product into the New Zealand market after signing an agreement with a key distributor.
Creso will introduce its cannaQIX 50 product in New Zealand, a cannabidiol lozenge designed to support the management of chronic pain.
Dr Miri Halperin Wernli, Creso CEO and co-founder, says the company is excited to launch the product into the world-class health system in New Zealand market.
"We are really excited to introduce cannaQIX 50 to New Zealand with CB Distributors," says Wernli.
"For Creso, New Zealand is an important market as it forms part of its overall APAC strategy, a region where projections suggest 23 per cent of the worldwide spend on CBD products will take place by 2022."
" is a young and highly motivated company with a genuine passion for the benefits cannabis can deliver to patients. This is a perfect fit with Creso's own philosophy and we anticipate a very successful collaboration." Read more
David Simmons - Business News Australia - 2 July 2018
Comments
Your email address will not be published.
We welcome relevant, respectful comments.